TickerFacts.

QuidelOrtho Corp (QDEL): Operating Cash Flow

Annual figures by period end, from SEC filings.

$105.20M
Year ended 2025-12-28
-$57.20M
Trailing 12 months to 2026-06-28
-50.8%
3-year compound annual growth
-30.1%
5-year compound annual growth
$885.30M2021-01-03: $629.70M2022-01-02: $805.90M2023-01-01: $885.30M2023-12-31: $280.20M2024-12-29: $83.00M2025-12-28: $105.20M$105.20M
2021-01-03 Operating Cash Flow (USD) 2025-12-28
Period endedOperating Cash FlowChange YoYSource filing
2025-12-28$105.20M+26.7%2026-02-19, From 2024-12-30
2024-12-29$83.00M-70.4%2026-02-19, From 2024-01-01
2023-12-31$280.20M-68.3%2026-02-19, From 2023-01-02
2023-01-01, Fiscal 2022$885.30M+9.9%2025-02-27, From 2022-01-03
2022-01-02, Fiscal 2021$805.90M+28.0%2024-08-01, From 2021-01-04
2021-01-03, Fiscal 2020$629.70Mn/a2023-02-23, From 2019-12-30

Operating Cash Flow at similar companies

Companies with the same SEC industry code (In Vitro & In Vivo Diagnostic Substances), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedOperating Cash FlowChange YoY
QuidelOrtho Corp (QDEL)2025-12-28$105.20M+26.7%
Idexx Laboratories Inc (IDXX)2025-12-31$1.18B+27.2%
Lantheus Holdings, Inc. (LNTH)2025-12-31$390.14M-28.4%
Neogen Corp (NEOG)2026-05-31$83.20M+43.0%
Myriad Genetics Inc (MYGN)2025-12-31$1.80Mn/m
Intellia Therapeutics, Inc. (NTLA)2025-12-31-$394.74Mn/m
Alpha Teknova, Inc. (TKNO)2025-12-31-$8.65Mn/m
Immucell Corp (ICCC)2025-12-31$2.48M+591.6%
Aspira Women's Health Inc. (AWHL)2025-12-31-$7.03Mn/m

Compare QDEL, IDXX, LNTH, NEOG side by side · Screen every company in In Vitro & In Vivo Diagnostic Substances ↗